Dr. Ravi Retnakaran, New combination therapy is game-changer in treatment of type 2 diabetes
Dr. Ravi Retnakaran, an endocrinologist at The Leadership Sinai Centre for Diabetes at Mount Sinai Hospital as well as a scientist at the hospital''s Lunenfeld-Tanenbaum Research Institute, discusses the importance of his team''s recent study in The Lancet for type 2 diabetes patients. His team shows that shows that, when combined with long-acting insulin, a new class of medication that mimics a naturally occurring gut hormone can obtain excellent blood sugar control – without increased risk of low sugars or weight gain, which are common side effects of the current drug treatments for patients with type 2 diabetes. Based on the study''s results, the research team at Mount Sinai Hospital is currently starting a new clinical trial (called PREVAIL) of this combination therapy. Patients are encouraged to call the Leadership Sinai Centre for Diabetes at Mount Sinai Hospital for further information, or click here.